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Abstract Article Info 
Introduction: Epstein Barr Virus (EBV) replicate in the epithelial cells and becomes latent in lymphocytes B. 
This virus is also associated with NPC, NHL, infectious mononucleosis and Burkitt’s lymphoma. The expression 
product of EBV acute infections can interact with genes in the epithelial cells to start the molecular level that 
leads to malignancy so that an increase in levels of IgA antibodies EA can indicate high levels of EBV infection. 
Objective: Comparing the level of IgA EA antibody for EBV between NPC WHO type III  and NHL.  
Method: Observational comparative analytic method with cross-sectional study design. The subject of this study 
are 16 NPC patients and 16 NHL patients, consists of 9 males and 7 females. Numeric data of IgA EA calculated 
by Mann Whitney and the categoric data is calculated by Kolmogorov Smirnov.  The examination of IgA EA 
level in EBV using ELISA method, with p-value <0.05. 
Result: This study reveals that there were increasing IgA EA levels in NPC patients (3.71±2.36) compared to 
NHL (0.27±0.20). There is a difference value of IgA EA in study groups both numerical and categorical. 
Conclusion: The level of IgA EA EBV antibody in NPC is higher than NHL. 
Keywords:  
IgA EA, NPC, NHL, EBV 
*Corresponding author:  
Address: Jalan Professor Eyckman No.38 Bandung 
40161, Indonesia 
 
e-mail: dr.arielanugrahani@gmail.com 
 
1. INTRODUCTION 
Nasopharyngeal Carcinoma (NPC) is an epithelial neoplasm arising 
from the fossa of Rosenmuller of the postnasal space [1]. Epstein-Barr virus 
(EBV) or human herpesvirus 4 is ubiquitous, and about 90% of adults 
throughout the world have antibodies against it. Acute infection is usually 
asymptomatic in immunocompetent children and manifests itself as 
mononucleosis in 30%-50% of immunocompetent adolescents and adults 
[2, 3]. This is a rare tumor in the most part of the world, but it occurs 
endemically in Southern China, Hong Kong, Singapore and some other part 
of Southeast Asia with high incidence [1, 2]. Epstein-Barr Virus (EBV) has 
long been implicated as an important etiological factor of NPC with 
histological evidence, indicating the consistent presence of the viral DNA 
and proteins in malignant tissue. The EBV is clonally present in virtually 
100% of undifferentiated NPC cases [3]. Epidemiology of NPC is unique, 
this disease is a malignancy that is rarely found in most parts of the world; 
endemic in South China (25 per 100,000 populations per year in 
Guangzhou), Hong Kong, Singapore, and parts of Southeast Asia. In 
Europe, the incidence of the disease is less than 1 per 100,000 population 
per year [3]. The incidence of NPC in Indonesia reaches 6.7 per 100,000 
population per year with the highest incidence of 4-5 decades and the ratio 
between men and women is 2-3:1.4. In Indonesia NPC ranks fourth in all 
malignancies after cervical, breast and skin cancer. The incidence increased 
in the last decade II and reached its peak at the age of 40-50 years and was 
ranked first in the ORL-HNS Health Sciences field which reached 28% of 
all cases of head and neck carcinoma. The prevalence of NPC in the 
Department of ORL-HNS Hasan Sadikin Hospital Bandung during the 
period of 2010-2014 was 39.4% [4]. 
Classification of NPC is histologically, namely keratinized squamous 
cell carcinoma (WHO type I), non-keratinized squamous cell carcinoma 
(WHO type II), and undifferentiated carcinoma (WHO type III). Factors that 
play a role in the pathogenesis of NPC include EBV, genetic susceptibility, 
and risk factors from the environment. Genetic susceptibility such as HLA-
A2 and HLA-BSin2 loci act as predisposing factors. Some environmental 
factors that are thought to be related to NPC are diet, exposure to chemicals 
in the workplace and tobacco [5]. 
Especially in immunocompromised patients, EBV is associated with various 
lymphoproliferative disorders and some neoplastic diseases, including Burkitt’s 
lymphoma and nasopharyngeal carcinoma. Like other herpes viruses, EBV has 
a productive lytic cycle and a latent phase. B lymphocytes are infected after the 
viral envelope glycoprotein gp350/220 has bound to the CD21 cell receptor, 
which is also the receptor for the C3d component of complement [6]. During the 
lytic cycle, regulatory proteins belonging to the immediately early antigen (IEA) 
and early antigen (EA) groups are synthesized to allow the production of viral 
DNA (EBVDNA), the virion structural proteins (viral capsid antigen, VCA) and 
membrane proteins (MA). Serologic testing for immunoglobulin A (IgA) 
antibodies directed against EBV viral capsid antigen (VCA/IgA) has identiﬁed 
as a valuable method to screen individuals for NPC [7, 8]. Moreover, serologic 
testing for IgA/VCA and IgA antibodies to EBV early antigen (IgA/EA) has been 
used widely to screen for NPC in the areas of China in which it is endemic [9]. 
The IARC 2009 working group on carcinogenicity of biological agents found 
sufficient evidence to infer the causality of the role of EBV in Burkitt's lymphoma, 
NHL associated immunosuppression, NK lymphoma/extranodal T cells (nose 
type), Hodgkin's lymphoma, and NPC [10]. The role of EBV in the more general 
types of NHL and in immunocompetent individuals is still unclear, mainly because 
the prevalence of EBV in adults is >90%, and lifetime latent infections occur in the 
memory of B cells. The mechanism of HIV-1 is positive, individuals who 
experience immune deficiency have a higher risk for NHL. Decreased immune 
function can cause reactivation and replication of EBV. Reacting EBV itself can be 
a risk factor for NHL. Non-Hodgkin's lymphoma is a lymphocyte cell malignancy, 
associated with immune dysregulation, a decrease in immunity resulting in immune 
response and lytic reactivation of herpesviruses such as EBV in mucous tissue.  
Immune dysregulation occurs due to loss of immune control due to reactivation of 
the herpes virus and the production of infectious viral particles, which triggers the 
serum IgA profile to reactivate herpes viruses such as EBV [11]. Pathogenesis of 
Non-Hodgkin Lymphoma (NHL) Lymphomas are solid tumors of lymphocyte 
origin and are the most common hematopoietic cancers, representing most common 
cancer, in terms of incidence rate, and the sixth in terms of cancer deaths, in both 
men and women in the United States. 3 Lymphomas represent diverse and 
heterogeneous groups of cancers, consisting of Hodgkin lymphoma, T cell and 
natural killer cell lymphoma, and various types of B cell non-Hodgkin lymphoma 
[7, 8]. Most types of B cell NHL correspond to B cells that have undergone various 
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molecular changes that occur after an initial encounter with antigen and exposure to 
helper T cells [5]. As these activation-promoting interactions occur in the germinal 
centers of lymph nodes and other lymphoid organs, these cells are referred to as 
post-germinal center B cells. The germinal center reaction involves rapid B cell 
proliferation and somatic DNA changes that result in both changes in the isotype of 
the Ig that is produced by these cells (from IgM to IgG or other isotypes), as well as 
enhanced antigen-binding afﬁnity [9]. 
The standard method of diagnosis of EBV is Immunofluorescence 
Assay (IFA), but because this method is not practical, subjective and 
relatively expensive, a method of enzyme-linked immunosorbent assay 
(ELISA) is developed. The ELISA method has better sensitivity and 
specificity than IFA, is quantitative, objective, costs are relatively cheap, 
and is suitable for population detection on a large scale [12]. 
2. MATERIAL AND METHODS 
This study is a comparative analytic observational study with cross-
section design. The research subjects were patients diagnosed with NPC and 
NHL in Hasan Sadikin Hospital from June 2016 to July 2017 who were in 
accordance with inclusion and exclusion criteria and were willing to 
participate in the study and sign an informed consent. 
Inclusion criteria: 1. WHO type III NPC patients from histopathological 
examination who have not undergone radiotherapy, chemotherapy, or 
combination therapy. 2. NHL patients from histopathological results who 
have not undergone chemotherapy. Exclusion criteria: 1. Patients with 
multiple carcinomas. 2. NPC and NHL residual/recurrent patients. 
The sample selection technique used in this study is nonprobability 
sampling with consecutive sampling method. There are 16 samples each for 
NPC and NHL samples. Every NPC and NHL patients who come to the 
hospital who has not received treatment therapy, checks starting from the 
history (history of patient complaints, symptoms, duration, and onset of 
disease and previous history), then a general physical examination. 
Nasopharyngoscopy, biopsy and immunohistochemical examination, and 
investigations (hepatobiliary ultrasound, chest X-ray, nasopharyngeal CT 
scan) in accordance with the applicable standard operating procedure. The 
examination was carried out using the ELISA method to obtain IgA EA EBV 
levels found in both NPC and NHL patient.  
3. RESULT 
Table 1. Comparison of the Characteristics of the Two Groups of 
Research Subjects by Age 
Variable 
Group 
P  NHL NPC 
n=16 n=16 
Age      
Mean±Std   52.18±8.93   46.81±16.42 0.262 
Median         52.50   50.00  
Range (min-max)         37.00-65.00   18.00-74.00  
Description: For the age of numerical data, the value of p is calculated based on the unpaired T-test 
because the data are normally distributed. ** Signs indicate significant or statistically significant.  
Table 2. Comparison of Characteristics of Both Study Subject Groups by Gender 
Variable 
Group 
P  NHL NPC 
n=16 n=16 
Gender   1.000 
    Man             9 (56.2%)       9 (56.2%)  
    Women  7 (43.8%) 7 (43.8%)  
Description: For gender categorical data p is calculated based on Chi-Square statistical significance 
value based on p value <0.05. ** Signs indicate significant or statistically significant 
 
In the table. 1 and table 2 of the NHL group found at an average age of 
52.18±8.93, male sex as many as 9 people or equal to 56.2%, and female sex at 
7 people or by 43.8%. In the NPC group, the average age was 46.81±16.42, male 
sex was 9 people or 56.2%, and female sex was 7 people or 43.8%. 
Statistical tests to compare the average numerical data with two 
unpaired groups, the analysis carried out using the unpaired T analysis test 
because the data are normally distributed, namely the age variable. The 
results of the statistical test on the age variable obtained a p-value of 0.262 
where the p-value is greater than 0.05 (p>0.05). So this shows not significant 
or not statistically significant. Thus it can be said that there is no difference 
in the average between age variables in the two study groups.  
For analysis on categorical data, namely, gender tested using Chi-Square 
statistical test, obtained p-value of 1.00 where this p-value is greater than 0.05     
(p>0.05) which means it is not significant or not statistically significant. Thus it 
can be explained that there is no difference in the proportion of significant or 
statistically significant between the two study groups. 
Based on the results of the characteristic analysis above, it can be concluded 
that in both groups there was no difference or the same or homogeneous. So that 
statistical tests can be carried out for further statistical hypothesis testing. 
Table 3. Comparison of EA IgA antibody levels with the two research groups 
No 
Titer  EA EBV IgA 
P  
NPC NHL 
   0.0001* 
1 1.81 0.19  
2 8.49 0.07  
3 1.91 0.16  
4 0.87 0.18  
5 4.63 0.19  
6 3.28 0.2  
7 4.38 0.7  
8 2.53 0.41  
9 0.85 0.64  
10 5.43 0.14  
11 4.05 0.46  
12 5.19 0.3  
13 1.77 0.09  
14 3.5 0.45  
15 2.14 0.11  
16 8.49 0.05  
    
Mean±Std 3.71±2.36 0.27±0.20   
Median 3.39 0.19   
Range (min-max) 0.85-8.49 0.05-0.70   
Description: For Numeric IgA EA data, the p-value is calculated based on the T-test not paired 
with Mann Whitney because the data is not normally distributed. Value of significance based on 
p-value <0.05. ** Signs indicate significant or statistically significant. 
 
In the table. 3 describes the comparison of IgA EA in both groups. 
Statistical tests to compare the average numerical data with two unpaired 
groups, the analysis carried out to test this numerical data using the Mann 
Whitney analysis test because the data are not normally distributed, namely 
the numerical EA IgA variable. The results of the statistical test on the IgA 
EA variable obtained a value of p-value of 0.0001 where the p-value was 
smaller than 0.05 (p<0.05). This shows significant or statistically 
significant. Thus it can be said that there are differences in the mean between 
the IgA EA variables in the two study groups. In the NHL group, the IgA 
EA value of 0.27±0.20 did not increase compared to the NPC group which 
had a higher average IgA EA than the NHL group which was 3.71±2.36. 
4. DISCUSSION 
In this study, the results of statistical tests obtained on the age variable 
obtained p-value of 0.262 where the p-value is greater than 0.05 (p>0.05). So this 
shows not significant or not statistically significant. Thus it can be said that there 
is no difference in the average between age variables in the two study groups. In 
this study, the highest age was obtained in patients with NPC and NHL in Hasan 
Sadikin Hospital between 40 to 50 years with an average age at NPC of 
52.18±8.93 and NHL at the age of 46.81±16.42. This is in accordance with 
Adham M et al. Getting the most age of NPC patients at the age of 40-50 years 
as much as 32.4% 2 and Cao SM et al in China getting the most age is decades 
4-6 [3, 13]. Ahmadi A et al. in research at Kermanshah, Iran, found patients with 
non-Hodgkin's lymphoma associated with EBV aged 45±13 years with a range 
of 28-73 years. Of the 12 patients (60%) male and 8 patients (40%) women [14]. 
The occurrence of NPC in the age range of 4-6 decades is caused by 
exposure to risk factors from the environment such as consumption of 
preserved and salted foods and exposure to carcinogenic substances that are 
long enough good so that it takes more time for the carcinogenesis process to 
occur [1-3, 6]. Nasopharyngeal carcinoma increases in humans according to 
age. There are differences in age-related tumor distribution patterns in various 
organs and tissues. Aging can increase or decrease the susceptibility of various 
tissues to the initiation of carcinogenesis and usually facilitates the promotion 
and progression of carcinogenesis. Aging can predispose to cancer through 
several mechanisms, namely the accumulation of tissue from cells in the later 
stages of carcinogenesis, changes in homeostasis, specifically changes in the 
immune system and endocrine system, telomere instability related to aging and 
increased risk of cancer [15]. 
The prevalence of EBV in NHL in adults is >90%, and EBV establishes a 
lifetime of latent infection in the memory of B cells. Mechanisms 
Immunocompromised individuals have a higher risk for NHL due to 
immunosuppression which causes increased replication of EBV and other 
carcinogenic viruses. Decreased immune function can cause reactivation and 
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replication of EBV. Psychological stress and aging can reduce the function of 
immune regulation and are involved in subclinical reactivation of EBV. 
Reactivation of EBV itself can be a risk factor for NHL. Besides,  external factor 
agents responsible for reducing immune function can cause EBV reactivation 
and an increased risk of NHL [16]. 
Most sufferers of NPC and NHL are men. This result is in accordance with 
Sudrajat's research which states that there are 14 male NPC patients and 9 female 
patients with a ratio of 1.5:1.35 [17].  The same results were also mentioned by 
Cahyadi et al .'s study of  male and female NPC patients with a ratio of 1.9:1.3 
[18]. Madani et al. In 2015 mentioned patients with NPC in the Department of 
ORL-HNS Hasan Sadikin hospital in the period 2010-2014, which showed more 
male sufferers with a ratio of men to women 2-3:1 [19]. Xiao et al. Reported men 
are diagnosed with NPC more than women, with 213 people (71.2%) and 86 
people (28.8%) respectively [20]. Tabyaoui et al., 2013 in Morocco getting a ratio 
between men and women is 2, 28:1. Boffetta, 2011, states that there are 356,000 
new cases of NHL and 192,000 cases with mortality from NHL spread in 2008. 
Non-Hodgkin's malignum lymphoma or non-Hodgkin's lymphoma is a primary 
malignant lymphoid tissue. More than 45,000 patients are diagnosed as non-
Hodgkin's lymphoma (LNH) every year in the United States. Non-Hodgkin's 
lymphoma, especially central nervous system lymphoma is commonly found in 
patients with immune deficiencies and who get immunosuppressive drugs. Non-
Hodgkin's Maligna lymphoma is the eighth-ranked malignancy found in men 
and ranks 11th in women. Countries with the highest incidence are in North 
America, Europe, Oceania and Africa. The incidence of NPC is more prevalent 
among men than women. This is because men are more exposed to 
environmental risk factors such as carcinogens, alcohol, and cigarette smoke. 
Also, exposure caused by work such as smoke, dust, steam, and chemicals as a 
risk factor for the occurrence of NPC is more common in men. In individual 
factors, there is a role for estrogen in women which has a protective effect against 
the progressive process of NPC, so there are fewer NPC patients in women than 
men [1-3, 15, 19-22].  
IgA EA levels in NPC were higher than NHL which was 3.71±2.36. This is 
based on the semi-quantitative interpretation of the IgA EA ratio with ELISA, ie 
Interpretation: negative if the ratio is <0.8, borderline if the ratio >=0.8 - <1, and 
positive if the ratio >=1.1. 
Sun, 2015, conducted a study in Shandong, China, found that there was an 
increase in serum IgA EA, IgA VCA and Sialic Acid (SA) in NPC patients. 
Immunoglobulin A VCA has a higher sensitivity (76.19%) compared to IgA EA 
and SA, but IgA EA has a high specificity (95.24%). This shows that EA is 
produced when EBV begins to replicate resulting in a high increase in specificity 
and low sensitivity. In Sun's study suggested a combination of examinations of 
IgA EA, VCA and SA IgA levels to obtain the right diagnosis and prognosis for 
NPC patients [13]. Shane et al. In their study found that there were serum IgA 
early lytic-antigen and Early Antigen-Diffuse (EA-D) in NHL sufferers. Early-
lytic antigens are significant in viral replication DNA [14]. One possible 
alternative is to look for additional serological markers that detect by ELISA, 
such as EA that reflects two different patterns initially observed using immuno-
fluorescence. About 70% -85% of patients with acute anti-EA EBV infection is 
positive antibodies up to three months after symptom onset. These high antibody 
titers during EBV reactivation and in NPC patients can also be found in                     
20%-30% of healthy subjects with a history of EBV infection [10, 13]. Detection 
of anti-EA antibodies alone is not possible to identify each stage of the disease, 
but the combination with other parameters may be useful for making a laboratory 
diagnosis of acute EBV infection. 
ELISA is the most sensitive semi-quantitative inspection method in 
detecting NPC. Positive serum numbers in NPC patients reach 100% via ELISA 
in a study. High sensitivity, fast sensitivity, enzyme-immunoassay is a handy tool 
for large-scale epidemiological studies for early diagnosis and monitoring of 
patients with nasopharyngeal carcinoma [20]. 
The Epstein Barr virus enters the human body and then replicates in 
epithelial cells and becomes latent in B lymphocytes. This viral infection occurs 
in two places, salivary gland epithelial cells, and lymphocyte cells. EBV begins 
to infect by binding to the C3d complement (CD21 or CR2). The mechanism of 
entry of EBV and the possibility of infection is possible by means of a direct 
connection between cells in the apical membrane with lymphocytes that have 
been infected with the virus. Besides that, it can be through the basolateral 
membrane, which is mediated by the interaction between integrins β1 or α5B1 
with EBV. Can also be through the spread of the virus directly through the lateral 
membrane that occurs after the first time infected with EBV. Viral infection in B 
lymphocytes is possible because of the bond between the glycoprotein 
gp350/220 membrane receptor on the EBV capsule and CD21 protein on the 
surface of B lymphocytes as the target. This process involves the interaction of 
several viral glycoprotein complexes including gH and gL which are 
homologous from the gp42 molecule with MHC class II in lymphocytes B. After 
binding to the CD21 receptor on lymphatic B, EBV within 1-2 hours will enter 
the host cell cytoplasm then fusion occurs TR, which causes the epitope to be 
circular in shape, EBV particles will decompose and the EBV genomes will enter 
the nucleus, which is a form of latent EBV infection, which is characterized by 
process of cell activation and proliferation called EBV activation on B 
lymphocyte cells [7, 8, 23, 24]. 
Under normal conditions, EBV infection can be controlled and enter the 
latent phase, where only a few B cells are infected. The lytic phase can occur both 
in the epithelium of the oral cavity and in B cells which are located adjacent to 
the epithelium of the oral cavity, which causes many infectious EBV in the oral 
cavity so that it can spread to other people. In malignancies associated with EBV, 
the EBV genome appears in each tumor cell in the form of a latent epicome, and 
the genome will replicate during cell division. The expression of DNA in EBV 
in the form of latent episomal can be used as a basis in detecting viral function in 
the development of NPC [4]. 
The initial steps of EBV lytic infection are characterized by ZEBRA protein 
activity encoded by the BZLF1 gene found in epithelial cells and B lymphocytes. 
Several different products from genes that have correlations with lytic replication 
cycle stages can be identified and categorized into EMA, EA, VCA, LMA. In 
latent infections, expression of several proteins occurs: Epstein Barr Nucleus 
Antigen 2 & 5 (EBNA 2 & 5) which can be detected 2-5 hours after infection, 
Latent Membrane Protein 1 & 2 (LMP 1 & 2) which can be detected 5-7 hours 
after infection. Latent infections that are silent and do not produce new viral 
particles are associated with one of them with NPC. The latent form of EBV 
infection in NPC includes type II with the expression characteristics of LMP 
proteins in addition to EBER and EBNA proteins [1, 10, 25, 26]. 
The exact mechanism by which EBV can induce cancer remains uncertain. 
However, further research on the expression of the LMP gene shows that it can 
alter nasopharyngeal epithelial cells in vitro, and it is estimated that LMP in cells 
infected with EBV protects these cells from a program of cell death or apoptosis. 
Whereas in other studies it was also found that the LMP gene was found in 65% 
of people with NPC [10].  
The etiology of non-Hodgkin's lymphoma is oncogenes, EBV infections, 
Human T-leukemia Virus-I (HTLV-I), autoimmune diseases and immune 
deficiency. More than 90% of non-Hodgkin's lymphoma is Mature B-cell 
neoplasm. In North America and Europe, B-cell lymphoma is Follicular 
Lymphoma. Whereas, in Asia, 80-90% form of diffuse lymphoma and T-cell 
lymphoma is more common. Lymphoma is differentiated based on cell type 
description of growth. Small cell types, intermediate and large cells, and the core 
form (cleaved and non-cleaved). In normal cell follicles polyclonal, whereas in 
monoclonal lymphoma cells with uniform morphological form and express the 
same immunoglobulin cells, namely light chain. Lymphoma originating from B 
cells can be identified with monoclonal antibodies that are specific to B-cells such 
as CD19, CD20, CD22, and CD79a. B lymphoma cells also have their 
immunophenotype component which requires multiparameter analysis. Small B-
cell lymphoma consists of B-CLL/SLL (B-cell chronic lymphocytic 
leukemia/small lymphocytic lymphoma), LPL (Lymphoplasmacytic 
lymphoma), MCL (Mantle cell lymphoma), FL (Follicular lymphoma), MZL 
(nodal marginal zone B -cell lymphoma) identified with monoclonal antibodies 
CD5, CD10, CD23, CD43, slg, cytolg, bcl-1 and bcl-6. But not one antigen is 
specific to one type of lymphoma, so an antibody panel is needed. The type of B 
lymphoma is important for prognosis and treatment [9, 11, 14, 16].  
In the WHO classification in 2008, the age of the patient was considered as 
a feature of some newly entered disease entities. For example, in the FL category 
and nodal MZLs there are distinctive variants that are almost exclusively in the 
child's age group and are different from clinically and biologically mature. FL 
pediatric variants are usually local and high histological classes. This lymphoma 
lacks BCL2/IGH translocation and does not express BCL-2 protein. They may 
involve nodal or extranodal sites (testis, digestive tract, Waldeyer's ring). 
Pediatric FL has a good prognosis, with optimal management better results. The 
difficulty of diagnosis is a rare case of reactive follicular hyperplasia in children 
who have been reported to contain B-cell clonal CD10+germinal center 
populations but have not progressed to lymphoma. Nodal MZL in children seems 
to have a low risk of progression. Most patients present with stage I disease and 
have a low risk of relapse after conservative therapy [10]. In contrast, some 
diseases appear to occur most frequently in the elderly, such as EBV+DLBCL 
from parents, which may arise due to decreased surveillance of immunology. 
This lymphoma is clinically aggressive and is more common in extranodal than 
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nodal sites. Neoplastic cells can resemble Hodgkin/Reed-Sternberg cells and 
show marked pleomorphism, with wider morphology than is usually seen in 
CHL. Necrosis and general inflammatory background. EBV+DLBCL parents 
must be distinguished from reactive hyperplasia associated with EBV, which is 
also found in older people, who usually have benign results, most of which 
experience spontaneous regression [14, 27].  
The antigen chosen for analysis represents a different phase of infection (ie 
primary, latent and reactive infection), and was chosen to increase the sensitivity of 
detection of EBV infection and potentially allow differentiation of the stages of 
infection. Immunoglobulin G (IgG) antibodies to viral capsid antigen (VCA) are 
produced within a few days of primary EBV infection and peak after 3-4 weeks. 
Furthermore, these antibodies decrease slowly but will remain throughout 
life. Antibodies for EBV nucleus antigen (EBNA) released in the subacute stage 
of the disease, and like VCA antibodies, persist indefinitely. BZLF1 encoded 
replicator activator (ZEBRA) is released during the lytic cycle in EBV 
permissive cells and antibodies are produced during primary EBV infection. 
ZEBRA is a key mediator of transition from latent to productive cycles on EBV 
and also as a virus reactivation marker. Antibodies to the initial antigen (EA) 
appear temporarily for up to 3 months during the acute phase of mononucleosis 
infection. During EBV reactivation due to immunosuppression, antibodies for 
EA increase quite high and persist in chronic infections [15, 23, 28, 29]. The 
limitation of this study is that it cannot determine the sensitivity and specificity 
of EA EBV IgA levels ELISA semiquantitatively because the results are divided 
according to positive, borderline, and negative values. 
5. CONCLUSION 
The EA EBV IgA antibody levels in WHO type III NPC were higher 
when compared to NHL. People with NPC and NHL are more likely to have 
male sex. The age of patients with NPC and NHL is highest in decades 4-6. 
NHL can give negative results on EA EBV IgA antibody examination and 
IgA EA cannot be used as early detection for NHL. 
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